All the news

Semaglutide, a medication approved to treat type 2 diabetes, increased the likelihood of improvement in non-alcoholic steatohepatitis (NASH) without worsening liver fibrosis, researchers reported at the AASLD virtual Liver Meeting. What's more, ...

Twenty-four weeks of treatment with lanifibranor, a drug designed to treat NASH, improved liver fibrosis in 42% of people treated in a phase 2b clinical trial, Professor Sven Francque of Antwerp ...

Efruxifermin reduced liver fat and improved liver inflammation and fibrosis in the majority of people with NASH who received it in a phase 2a trial but nausea and vomiting led 10% of ...

Cotadutide, an experimental therapy that alters glucose and lipid metabolism, led to weight loss and improvements in metabolic, cardiovascular and liver fibrosis biomarkers in overweight people with diabetes and fatty liver disease, but ...

Combinations of experimental drugs for non-alcoholic steatohepatitis (NASH) failed to meet a study's primary endpoint by significantly improving liver fibrosis without worsening NASH, but one combination in particular – firsocostat plus ...

Aldafermin significantly reduced liver fat content and liver damage in a phase 2 study of a 24-week treatment course, Dr Stephen Harrison, Visiting Professor of Hepatology at the University of Oxford, told ...

People living with HIV who have non-alcoholic fatty liver disease (NAFLD) often have liver fibrosis and are at risk for fibrosis worsening, researchers reported earlier this month at the Conference ...